RxDoctor Payments Data

Abigail Wilhite, MD

Family Medicine · Murfreesboro, ARNPI 1073076550

Payments from drug & device makers

$459in general payments, 2019–2025

Across 21 payments — averaging $21.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eisai Inc.$102
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$97
  • Lilly USA, LLC$75
  • Otsuka America Pharmaceutical, Inc.$67
  • AbbVie$48
  • AstraZeneca$22
  • plus $48 from 3 others

What the payments were for

  • Food & beverage$459100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$459 in reported general payments places this provider in the 45th percentile of 1,347 family medicine providers in Arkansas.

See all family medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$17,275
Medicare patients
209
Services billed
1,393

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban239$97,446
MounjaroTirzepatide85$90,065
OzempicSemaglutide85$82,450
JardianceEmpagliflozin117$63,083
JanuviaSitagliptin Phosphate100$52,780
TrulicityDulaglutide42$49,526
FarxigaDapagliflozin Propanediol75$43,229
LinzessLinaclotide31$23,052
EntrestoSacubitril/Valsartan70$21,261
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$20,826
MyrbetriqMirabegron18$18,722
TresibaInsulin Degludec50$18,236
Divalproex Sodium213$14,166
Tresiba Flextouch U-100Insulin Degludec22$12,000
Janumet XrSitagliptin Phos/Metformin Hcl38$9,429

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$75$139,591127 claims
Novo NordiskOzempic, Tresiba, Levemir$16$102,326149 claims
AstraZenecaFarxiga, Breztri Aerosphere, Brilinta$22$56,415113 claims
AbbVieLinzess$48$23,05231 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,347 family medicine providers in Arkansas.

Other family medicine in Murfreesboro

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →